MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/ejhf/xuag295

Медицинская библиотека · European journal of heart failure · 2026

Kidney function decline, heart failure hospitalization, and the effect of empagliflozin in heart failure: an EMPEROR-pooled analysis.

Kobayashi Masatake, Duarte Kevin, Baudry Guillaume, Ferreira João Pedro, Monzo Luca, Butler Javed, Zannad Faiez, Girerd Nicolas

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Kidney function decline in heart failure (HF) may accelerate during periods surrounding HF-related events, while sodium-glucose cotransporter 2 inhibitors slow kidney function decline. However, the temporal relationship between kidney function changes, HF-related events, and treatment effects has not been well characterized.

AIMS: We aimed to explore kidney function trajectories around HF-related events and to assess whether empagliflozin modifies these changes.

METHODS AND

RESULTS

In a pooled analysis of the EMPEROR-Reduced and EMPEROR-Preserved trials, we examined longitudinal changes in estimated glomerular filtration rate (eGFR) before and after HF-related events, defined as HF hospitalization or HF-related death. In the EMPEROR-Pooled analysis, HF-related events occurred in 12.7% of 9554 patients during a median follow-up of 20.9 months (14.7-28.6). Patients who experienced HF-related events had a steeper eGFR decline during the 12 months before the event than those without HF-related events: average -5.01 ml/min/1.73 m2/year vs -1.93 ml/min/1.73 m2/year; P < .001. During the 12 months after HF-related events, eGFR decline persisted at an average rate of -4.73 ml/min/1.73 m2/year. These trajectories were not materially altered after adjustment for concurrent NYHA class or natriuretic peptide levels. Compared with placebo, empagliflozin slowed eGFR decline in patients without events (between-group difference, 0.94 ml/min/1.73 m2/year) and before events (1.09 ml/min/1.73 m2/year). The post-event difference was smaller (0.29 ml/min/1.73 m2/year), without significant heterogeneity across periods (P > .10). Findings were consistent across trials and irrespective of prior HF hospitalization.

CONCLUSION

Across the LVEF spectrum, kidney function decline accelerated before HF-related events and remained rapid thereafter. Empagliflozin attenuated eGFR decline without evidence of heterogeneity across periods.

Для цитирования: Kobayashi Masatake, Duarte Kevin, Baudry Guillaume, Ferreira João Pedro, Monzo Luca, Butler Javed, Zannad Faiez, Girerd Nicolas. Kidney function decline, heart failure hospitalization, and the effect of empagliflozin in heart failure: an EMPEROR-pooled analysis.. European journal of heart failure. 2026. DOI: 10.1093/ejhf/xuag295.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.